June 11, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
NEW ORLEANS —Adolescents with new-onset type 2 diabetes and obesity were more likely to achieve an HbA1c of less than 6% at 1 year with sleeve gastrectomy compared with treat-to-target medical therapy, researchers reported. Amy S. Shah, MD, MS, FNLA, director of the division of endocrinology at Cincinnati Children’s Hospital, said the SURPASS-PEDS trial showed tirzepatide
June 11, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

NEW ORLEANS — Fewer than half of children and adolescents with type 2 diabetes are prescribed GLP-1 receptor agonists at most…

Youths who start using an automated insulin delivery system within 6 months of type 1 diabetes diagnosis are 82% more likely to…

NEW ORLEANS — Adults with type 2 diabetes who were provided medically tailored healthy meals and lifestyle counseling for 6…

NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with…

NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes,…

Semaglutide combined with counseling 'emerged as the most potent intervention'

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

Em quais casos a tirzepatida pode ser indicada para adolescentes?